Duvelisib + Nivolumab for the Treatment of MF and SS

Brief Summary:

This phase I trial identifies the best dose, possible benefits, and/or side effects of duvelisib in combination with nivolumab in treating patients with stage IIB-IVB mycosis fungoides and Sezary syndrome. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving duvelisib in combination with nivolumab may work better than giving each of these drugs individually, or treating with the usual approach in patients with mycosis fungoides and Sezary syndrome.

Website: https://clinicaltrials.gov/ct2/show/NCT04652960?term=Duvelisib+%2B+Nivolumab&draw=2&rank=3

Sponsors and Collaborators

National Cancer Institute (NCI)


Principal Investigator: Neha Mehta-Shah Yale University Cancer Center LAO

Contacts and Locations

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04652960


Participating Locations:

University of Pittsburgh Medical Center
Pittsburgh, PA, United States
Sue McCann, MSN, RN, DNC